Internal Reference Number: FOI_8741
Date Request Received: 03/07/2025 00:00:00
Date Request Replied To: 25/07/2025 00:00:00
This response was sent via: By Email
Request Summary: Diffuse Large B Cell Lymphoma (DLBCL)
Request Category: Private Individuals
| Question Number 1: In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? a. Of these patients, how many commenced treatment at your trust within the last 6 months? | |
| Answer To Question 1: In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? 9 Of these patients, how many commenced treatment at your trust within the last 6 months? 7 | |
| Question Number 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: 鈥� R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) 鈥� R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) 鈥� Pola-BR (polatuzumab vedotin with rituximab and bendamustine) 鈥� Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) 鈥� R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) 鈥� R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) 鈥� R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) 鈥� (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) 鈥� R-GemOX (rituximab, gemcitabine and oxaliplatin) 鈥� Axicabtagene ciloleucel 鈥� Tisagenlecleucel 鈥� Epcoritamab 鈥� Loncastuximab tesirine 鈥� Glofitamab 鈥� Any other SACT 鈥� Stem cell transplant or bone marrow transplant (autologous or allogeneic) | |
| Answer To Question 2: See attachment To accompany this answer to question 2 please also see the documents listed below:  13107 - FOI_8741 - Diffuse Large B Cell Lymphoma (DLBCL) v1 FOR ISSUE.docx | |
| Question Number 3: . In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): 鈥� Axicabtagene ciloleucel (Yescarta) 鈥� Tisagenlecleucel 鈥� Pola-BR (polatuzumab vedotin with rituximab and bendamustine) 鈥� R-GemOX (rituximab, gemcitabine and oxaliplatin) 鈥� Stem cell transplant or bone marrow transplant (autologous or allogeneic) 鈥� Any other treatments | |
| Answer To Question 3: For axicabtagene, tisagenlecleucel, RGemOx, stem cell transplant - Zero patients <5 patients for other treatment, <5 patients for pola-BR | |
| Question Number 4: In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? | |
| Answer To Question 4: <5 patients | |
| Question Number 5: In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: 鈥� CAR-T Therapy (E.g. Axicabtagene ciloleucel) 鈥� Stem cell transplant or bone marrow transplant (autologous or allogeneic) 鈥� Any other treatment | |
| Answer To Question 5: None | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
